Document Detail


Maintenance chemotherapy and inmunotherapy in acute lymphoblastic leukemia (author's transl)
MedLine Citation:
PMID:  6950685     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Sixty-one children with ALL were treated between 1970 an 1973 according to a scheme including: a) Remission induction with vincristine-prednisolone-daunorubicine. b) Cytoreduction therapy with 4 drugs (6-MP, MTX,Ara-C and CYCLO) combined two by two in 3 types of associations given at three months cycles. Every three months, two-week "reinductions" with vincristine and prednisolone plus one dose of i.t. MTX. c) Early therapy on CNS, according to two patterns: one group received one dose of i.t. MTX after induction, repeated every 3 months; the other group was given cranial irradiation [2,400 r] plus 5 doses of i.t. MTX. d) After three years of chemotherapy, patients were treated for two more years with BCG by scarification. Results: Complete remission was achieved in 93%. After three years of chemotherapy, 37% of the first group (not irradiated) and 55% of the second (irradiated) persisted in C.R. Twenty-five patients initiated BCG-therapy; eighteen of these (72%) persisted, after 2 years, in C.R.; then all treatment was suppressed. Initial relapses in the 5 years period were hematological in 13, CNS in 13, both hematological and CNS in 2, and testicular in 3. Mortality of patients in C.R. was 4 (7.7%). Survival rates were 33% after 5 years for the non-irradiated group and 50% in the irradiated one. At present, 30% of all evaluable patients who attained remission continue in C.R. after an average time of 102 months-40% in the irradiated group and 20% in the not irradiated-. This difference, statistically significant, is due to the number of CNS relapses: 13 of 30 (43%) in the first group and 3 of 22 (13.1%) in the second. The 24% relapses occurring during immunotherapy do not permit to assess the efficacy of this form of therapy.
Authors:
J J Ortega; G Javier
Publication Detail:
Type:  Clinical Trial; Controlled Clinical Trial; English Abstract; Journal Article    
Journal Detail:
Title:  Anales españoles de pediatría     Volume:  15     ISSN:  0302-4342     ISO Abbreviation:  An. Esp. Pediatr.     Publication Date:  1981 Oct 
Date Detail:
Created Date:  1982-05-21     Completed Date:  1982-05-21     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  0420463     Medline TA:  An Esp Pediatr     Country:  SPAIN    
Other Details:
Languages:  spa     Pagination:  357-64     Citation Subset:  IM    
Vernacular Title:
Terapéutica de mantenimiento con quimioterapia seguida de inmunoterapia en L.A.L. infantiles (protocolo C-70).
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Antineoplastic Agents / administration & dosage*
BCG Vaccine / adverse effects,  therapeutic use
Child
Child, Preschool
Drug Therapy, Combination
Female
Humans
Infant
Leukemia, Lymphoid / mortality,  therapy*
Male
Prognosis
Random Allocation
Chemical
Reg. No./Substance:
0/Antineoplastic Agents; 0/BCG Vaccine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Blastomycosis in immunosuppressed patients.
Next Document:  The major histocompatibility complex.